Table 1.
The clinical and tumor characteristics between patients with bone metastasis and patients without bone metastasis
| Characteristic | All patients (N = 55,869) | Patients without BM (N = 55,552) | Patients with BM (N = 317) | BM rate (%) |
|---|---|---|---|---|
| Age at diagnosis (years) | ||||
| < 60 | 19,665 (35.2%) | 19,529 (35.2%) | 136 (42.9%) | 0.69 |
| ≥ 60 | 36,204 (64.8%) | 36,023 (64.8%) | 181 (57.1%) | 0.50 |
| Sex | ||||
| Female | 26,804 (48.0%) | 26,674 (48.0%) | 130 (41.0%) | 0.49 |
| Male | 29,065 (52.0%) | 28,878 (52.0%) | 187 (59.0%) | 0.64 |
| Tumor location | ||||
| Colon | 45,414 (81.3%) | 45,176 (81.3%) | 238 (75.1%) | 0.52 |
| Rectum | 10,455 (18.7%) | 10,376 (18.7%) | 79 (24.9%) | 0.76 |
| Grade | ||||
| Well-Moderate differentiation | 44,840 (80.2%) | 44,639 (80.4%) | 201 (63.4%) | 0.45 |
| Poorly-Undifferentiation | 11,029 (19.8%) | 10,913 (19.6%) | 116 (36.6%) | 1.05 |
| Histological type | ||||
| Adenocarcinoma | 50,201 (89.8%) | 49,929 (89.9%) | 272 (85.8%) | 0.54 |
| Mucinous adenocarcinoma | 4,543 (8.1%) | 4,521 (8.1%) | 22 (6.9%) | 0.48 |
| Signet-ring cell carcinoma | 1,125 (2.1%) | 1,102 (2.0%) | 23 (7.3%) | 2.04 |
| CEA | ||||
| (−) | 31,446 (56.3%) | 31,386 (56.5%) | 60 (18.9%) | 0.19 |
| (+) | 24,423 (43.7%) | 24,166 (43.5%) | 257 (81.1%) | 1.05 |
| Tumor size (cm) | ||||
| < 2 | 5,012 (9.0%) | 5,001 (9.0%) | 11 (3.5%) | 0.22 |
| 2–5 | 26,001 (46.5%) | 25,882 (46.6%) | 119 (37.5%) | 0.46 |
| ≥ 5 | 24,856 (44.5%) | 24,669 (44.4%) | 187 (59.0%) | 0.75 |
| AJCC TNM stage | ||||
| I | 10,209 (18.3%) | 10,209 (18.4%) | 0 | – |
| II | 17,151 (30.7%) | 17,151 (30.9%) | 0 | – |
| III | 19,322 (34.6%) | 19,322 (34.8%) | 0 | – |
| IV | 9,187 (16.4%) | 8,870 (15.9%) | 317 (100%) | 3.45 |
| AJCC T stage | ||||
| T1/T2 | 13,363 (23.9%) | 13,320 (24.0%) | 43 (13.6%) | 0.32 |
| T3/T4 | 42,506 (76.1%) | 42,232 (76.0%) | 274 (86.4%) | 0.64 |
| AJCC N stage | ||||
| N0 | 29,312 (52.5%) | 29,242 (52.6%) | 70 (22.1%) | 0.24 |
| N1/N2 | 26,557 (47.5%) | 26,310 (47.4%) | 247 (77.9%) | 0.93 |
| AJCC M stage | ||||
| M0 | 46,682 (83.6%) | 46,682 (84.0%) | 0 | – |
| M1 | 9,187 (16.4%) | 8,870 (16.0%) | 317 (100%) | 3.45 |
| Extraosseous metastasis | ||||
| No | 48,735 (87.2%) | 48,674 (87.6%) | 61 (19.2%) | 0.13 |
| Yes | 7,134 (12.8%) | 6,878 (12.4%) | 256 (80.8%) | 3.59 |
| Brain metastasis | ||||
| No | 55,783 (99.8%) | 55,480 (99.9%) | 303 (95.6%) | 0.54 |
| Yes | 86 (0.2%) | 72 (0.1%) | 14 (4.4%) | 16.28 |
| Liver metastasis | ||||
| No | 49,332 (88.3%) | 49,237 (88.6%) | 95 (30.0%) | 0.19 |
| Yes | 6,537 (11.7%) | 6,315 (11.4%) | 222 (70.0%) | 3.40 |
| Lung metastasis | ||||
| No | 54,215 (97.0%) | 54,027 (97.3%) | 188 (59.3%) | 0.35 |
| Yes | 1,654 (3.0%) | 1,525 (2.7%) | 129 (40.7%) | 7.80 |
N Number, BM Bone Metastasis